Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2019.12.08
- Author:
Xiaoyu ZHI
1
;
Weiwei LI
2
;
Shaowei WANG
3
;
Jinliang WANG
1
Author Information
1. Department of Medical Oncology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
2. Department of Medical Oncology, the Hospital of 81st Group Army PLA, Zhangjiakou 075000, China.
3. Key Laboratory of Cancer Center, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
- Publication Type:Journal Article
- Keywords:
EGFR mutation;
Lung neoplasms;
PD-1/PD-L1 inhibitors;
PD-L1
- From:
Chinese Journal of Lung Cancer
2019;22(12):779-785
- CountryChina
- Language:Chinese
-
Abstract:
Researches on the inhibitors of programmed death-1 (PD-1) and programmed death-1 ligand (PD-L1) enjoy considerable breakthroughs in recent years, which has brought relative changes in the therapeutic model of non-small cell lung cancer (NSCLC) at an unexpected speed. However, it seems that PD-1/PD-L1 inhibitors are less effective in patients with epidermal growth factor receptor (EGFR) mutation than those without. Previous studies have shown that the expression rate of PD-L1 on tumor cells is correlated with the therapeutic effect of PD-1/PD-L1 inhibitors. Yet, there is no complete agreement on the effect of EGFR mutation on PD-L1 expression. In this review, relevant studies will be summarized with an expectation of making some contributions to basic researches and to the clinical treatment.
